The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis

What Was Tested

The paper reports a study of Teriparatide and Parathyroid Hormone (PTH 1-84) in the context of osteoporosis and bone density, published as a randomized controlled trial.

The researchers randomized 437 men with spine or hip bone mineral density more than 2 SD below the young adult male mean to daily injections of placebo, teriparatide 20 microg, or teriparatide 40 microg.

All subjects also received supplemental calcium and vitamin D.

Who Took Part

The study group was 437 men.

The age groups tagged for this paper are adults, middle-aged adults, older adults and people over 80, men only.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Because people in this Teriparatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The comparison arm used a placebo, so changes seen with Teriparatide could be set against what happens without it.

The timeline in the abstract includes 3 months.

What Was Measured

Topics PubMed links to this paper include Bone Density, Bone Neoplasms, Bone Remodeling, Osteoporosis, Osteosarcoma, Rats and Rats, Inbred F344.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Teriparatide and Parathyroid Hormone (PTH 1-84) in 437 men in people with osteoporosis and bone density over 3 months.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2003 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: the Teriparatide compound page and the Parathyroid Hormone (PTH 1-84) compound page, Osteoporosis and bone density research.